145 related articles for article (PubMed ID: 38271200)
21. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
22. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.
Kaifi JT; Zinnkann U; Yekebas EF; Schurr PG; Reichelt U; Wachowiak R; Fiegel HC; Petri S; Schachner M; Izbicki JR
World J Gastroenterol; 2006 Jan; 12(1):94-8. PubMed ID: 16440424
[TBL] [Abstract][Full Text] [Related]
23. [Exocrine meets neuroendocrine: mimickers of pancreatic neuroendocrine neoplasms].
Karamitopoulou-Diamantis E
Pathologie (Heidelb); 2024 Feb; 45(1):42-49. PubMed ID: 38091082
[TBL] [Abstract][Full Text] [Related]
24. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
[TBL] [Abstract][Full Text] [Related]
25. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
26. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin.
Viale G; Doglioni C; Gambacorta M; Zamboni G; Coggi G; Bordi C
Cancer; 1992 Nov; 70(9):2268-77. PubMed ID: 1356613
[TBL] [Abstract][Full Text] [Related]
27. [Gastroenteropancreatic neuroendocrine neoplasms. Role of biopsies].
Bergmann F
Pathologe; 2013 Nov; 34 Suppl 2():221-5. PubMed ID: 24196617
[TBL] [Abstract][Full Text] [Related]
28. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
29. TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas.
Jiang Y; Xie J; Wang B; Mu Y; Liu P
Hum Pathol; 2018 Nov; 81():166-175. PubMed ID: 30030118
[TBL] [Abstract][Full Text] [Related]
30. Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Pancreas.
Tsvetkova V; Luchini C
Surg Pathol Clin; 2022 Sep; 15(3):555-563. PubMed ID: 36049836
[TBL] [Abstract][Full Text] [Related]
31. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
Fang JM; Shi J
Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
[TBL] [Abstract][Full Text] [Related]
32. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
33. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.
Czeczok TW; Stashek KM; Maxwell JE; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):94-100. PubMed ID: 29420353
[TBL] [Abstract][Full Text] [Related]
34. [Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls].
Bräutigam K; Chouchane A; Konukiewitz B; Perren A
Pathologie (Heidelb); 2024 Feb; 45(1):35-41. PubMed ID: 38175232
[TBL] [Abstract][Full Text] [Related]
35. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
36. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
38. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.
Viehweger F; Tinger LM; Dum D; Gorbokon N; Menz A; Uhlig R; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Krech R; Krech T; Marx AH; Simon R; Burandt E; Steurer S; Sauter G; Minner S; Bernreuther C
Anal Cell Pathol (Amst); 2022; 2022():6412148. PubMed ID: 35992051
[TBL] [Abstract][Full Text] [Related]
40. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
